These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23401458)

  • 21. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
    [No Abstract]   [Full Text] [Related]  

  • 22. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
    Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
    Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
    Garon EB; Brodrick P
    Drugs; 2021 Apr; 81(5):547-554. PubMed ID: 33638808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
    Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
    Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
    Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
    J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].
    Yu X; Xu Y; Fan Y
    Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):287-292. PubMed ID: 28442019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The METeoric rise of MET in lung cancer.
    Friedlaender A; Drilon A; Banna GL; Peters S; Addeo A
    Cancer; 2020 Nov; 126(22):4826-4837. PubMed ID: 32888330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].
    Jiang T; Zhou C
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):240-4. PubMed ID: 25936889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
    Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.